Obesity and diabetes: the final frontier

References

• Maggio CA, Pi-Sunyer FX. Obesity and type 2 diabetes. Endocrinol Metab Clin North Am. 2003;32(4):805–822.
   PubMed Web of Science ®Google Scholar
• Al-Goblan AS, Al-Alfi MA, Khan MZ. Mechanism linking diabetes mellitus and obesity. Diabetes Metab Syndr Obes. 2014;7:587–591.
   PubMedGoogle Scholar
• Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444(7121):840–846. 14.
   PubMed Web of Science ®Google Scholar
• Pulgaron ER, Delamater AM. Obesity and type 2 diabetes in children: epidemiology and treatment. Curr Diab Rep. 2014;14:508.
   PubMed Web of Science ®Google Scholar
• Bullard KM, Cowie CC, Lessem SE, et al. Prevalence of diagnosed diabetes in adults by diabetes type—United States, 2016. Mmwr. 2018;67:359–361.
   PubMed Web of Science ®Google Scholar
• Fujioka S, Matsuzawa Y, Tokunaga K, et al. Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism. 1987;36(1):54–59.
   PubMed Web of Science ®Google Scholar
• Despres JP, Nadeau A, Tremblay A, et al. Role of deep abdominal fat in the association between regional adipose tissue distribution and glucose tolerance in obese women. Diabetes. 1989;38(3):304–309.
   PubMed Web of Science ®Google Scholar
• Pouliot MC, Despres JP, Nadeau A, et al. Visceral obesity in men. Associations with glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes. 1992;41(7):826–834.
   PubMed Web of Science ®Google Scholar
• Park KS, Rhee BD, Lee KU, et al. Intra-abdominal fat is associated with decreased insulin sensitivity in healthy young men. Metabolism. 1991;40(6):600–603.
   PubMed Web of Science ®Google Scholar
• Rendell MS. Current and emerging gluconeogenesis inhibitors for the treatment of Type 2 diabetes. Expert Opin Pharmacother. 2021;16(16):2167–2179.
   Google Scholar
• Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiol Rev. 2018Oct1;98(4):2133–2223.
   PubMed Web of Science ®Google Scholar
• Schinner S, Scherbaum WA, Bornstein SR, et al. Molecular mechanisms of insulin. Diabet Med. 2005;22(6):674–682.
   PubMed Web of Science ®Google Scholar
• Dahik VD, Frisdal E, Le Goff W. Rewiring of lipid metabolism in adipose tissue macrophages in obesity: impact on insulin resistance and type 2 diabetes. Int J Mol Sci. 2020;21(15):5505.
   PubMed Web of Science ®Google Scholar
• Chadt A, Scherneck S, Joost HG, et al. Molecular links between obesity and diabetes: “Diabesity.” In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000.
   Google Scholar
• Scheen AJ, Van Gaal LF. Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. Lancet Diabetes Endocrinol. 2014;2(11):911–922.
   PubMed Web of Science ®Google Scholar
• Tabák AG, Jokela M, Akbaraly TN, et al., Trajectories of glycemia, insulin sensitivity and insulin secretion preceding the diagnosis of type 2 diabetes: the Whitehall II study. Lancet. 2009;373(9682): 2215–2221.
   PubMed Web of Science ®Google Scholar
• Vistisen D, Witte DR, Tabak AG, et al. Patterns of obesity development before the diagnosis of type 2 diabetes: the Whitehall II Cohort Study. PLoS Med. 2014;11(2):e1001602.
   PubMed Web of Science ®Google Scholar
• Nuttall FQ. Body mass index. Nutrition Today. 2015 May;50:117–128.
   PubMedGoogle Scholar
• Sharma AM, Kushner RF. A proposed clinical staging system for obesity. Int J Obes (Lond). 2009;33:289–295.
   PubMed Web of Science ®Google Scholar
• Flegal KM, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA. 2012;307:491–497.
   PubMed Web of Science ®Google Scholar
• Hales CM, Carroll MD, Fryar CD, et al. Prevalence of obesity and severe obesity among adults: United States, 2017–2018. Hyattsville (MD): National Center for Health Statistics; 2020. NCHS Data Brief, no 360.
   Google Scholar
• Ellison-Barnes A, Johnson S, Gudzune K. Trends in obesity prevalence among adults aged 18 through 25 years, 1976-2018. JAMA. 2021;326(20):2073–2074.
   PubMed Web of Science ®Google Scholar
• O’Brien PE, Dixon JB. The extent of the problem of obesity. Am J Surg. 2002;184(Supp 2):S4–S8.
   Google Scholar
• Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9:88.
   PubMed Web of Science ®Google Scholar
• Boye KS, Lage MJ, Terrell K. Healthcare outcomes for patients with type 2 diabetes with and without comorbid obesity. J Diabetes Complications. 2020;34:107730.
   PubMedGoogle Scholar
• Pischon T, Boeing H, Hoffmann K, et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med. 2008;359:*Mortality associated with obesity; 2105–2120.
   PubMed Web of Science ®Google Scholar
• Berenson GS, Srinivasan SR, Bao WH, et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. N Engl J Med. 1998;338:1650–1656.
   PubMed Web of Science ®Google Scholar
• Powell-Wiley TM, Poirier P, Burke LE et al. Obesity and cardiovascular disease. A scientific statement from the American Heart Association. Circulation. 2021;143:e984–e1010.
   PubMed Web of Science ®Google Scholar
• Matza LS, Yurgin N, Boye KS, et al. Obese versus non-obese patients with type 2 diabetes: patient-reported outcomes and utility of weight change. Curr Med Res Opin. 2009;9:2051–2062.
   Google Scholar
• Tobias D, Pan A, Hu FB. BMI and mortality among adults with incident type 2 diabetes. N Engl J Med. 2014;370:1363–1364.
   PubMedGoogle Scholar
• Kritchevsky SB, Beavers KM, Miller ME, et al. Intentional weight loss and all-cause mortality: a meta-analysis of randomized clinical trials. PLoS One. 2015;10:e0121993.
   PubMed Web of Science ®Google Scholar
• Clifton PM, Keogh JB. Effects of different weight loss approaches on CVD risk. Curr Atheroscler Rep. 2018;20:27.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84.
   PubMed Web of Science ®Google Scholar
• Portillo-Sanchez P, Bril F, Maximos M, et al. High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. J Clin Endocrinol Metab. 2015;100:2231–2238.
   PubMed Web of Science ®Google Scholar
• Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313:2263–2273.
   PubMed Web of Science ®Google Scholar
• Romero-Corral A, Caples SM, Lopez-Jimenez F, et al. Interactions between obesity and obstructive sleep apnea: implications for treatment. Chest. 2010;137:711–719.
   PubMed Web of Science ®Google Scholar
• Parish JM, Somers VK. Obstructive sleep apnea and cardiovascular disease. Mayo Clin Proc. 2004;79:1036–1046.
   PubMed Web of Science ®Google Scholar
• Lavie P, Lavie L, Herer P. All-cause mortality in males with sleep apnoea syndrome: declining mortality rates with age. Eur Respir J. 2005;25:514–520.
   PubMed Web of Science ®Google Scholar
• Marti S, Sampol G, Mun ̃oz X, et al. Mortality in severe sleep apnea/hypopnea syndrome patients: impact of treatment. Eur Respir J. 2002;20:1511–1518.
   PubMed Web of Science ®Google Scholar
• Kuna ST, Reboussin DM, Strotmeyer ES, et al. Effects of weight loss on obstructive sleep apnea severity. Ten-year results of the sleep AHEAD study. Am J Respir Crit Care Med. 2021;203:221–229.
   PubMed Web of Science ®Google Scholar
• Berridge KC. Wanting and liking: observations from the neuroscience and psychology laboratory. Inquiry (Oslo). 2009 Aug 1;52(4):378.
   PubMed Web of Science ®Google Scholar
• Volkow ND, Michaelides M, Baler R. The neuroscience of drug reward and addiction. Physiol Rev. 2019;99:2115–2140. 4.
   PubMed Web of Science ®Google Scholar
• Kinasz KR, Ross DA, Cooper JJ. Eat to live or live to eat? The neurobiology of appetite regulation. Biol Psychiatry. 2017;81(9):e73–e75.
   PubMed Web of Science ®Google Scholar
• Farr OM, Li CR, Mantzoros CS. Central nervous system regulation of eating: insights from human brain imaging. Metabolism. 2016;65(5):699–713.
   PubMed Web of Science ®Google Scholar
• Campos A, Port JD, Acosta A. Integrative hedonic and homeostatic food intake regulation by the central nervous system: insights from neuroimaging. Brain Sci. 2022;12(4):431.
   PubMed Web of Science ®Google Scholar
• Ahima RS, Antwi DA. Brain regulation of appetite and satiety. Endocrinol Metab Clin North Am. 2008;37(4):811–823.
   PubMed Web of Science ®Google Scholar
• Löffler MC, Betz MJ, Blondin DP, et al. Challenges in tackling energy expenditure as obesity therapy: from preclinical models to clinical application. Mol Metab. 2021;51:101237.
   PubMed Web of Science ®Google Scholar
• Chen KY, Brychta RJ, Abdul Sater Z, et al. Opportunities and challenges in the therapeutic activation of human energy expenditure and thermogenesis to manage obesity. J Biol Chem. 2020;295(7):1926–1942.
   PubMed Web of Science ®Google Scholar
• Busiello RA, Savarese S, Lombardi A. Mitochondrial uncoupling proteins and energy metabolism. Front Physiol. 2015;6:36.
   PubMed Web of Science ®Google Scholar
• Dani C. Activins in adipogenesis and obesity. Int J Obes. 2013;37:163–166.
   Web of Science ®Google Scholar
• Stunkard AJ, Sørensen TI, Hanis C, et al. An adoption study of human obesity. N Engl J Med. 1986;314:193–198.
   PubMed Web of Science ®Google Scholar
• Rohde K, Keller M, la Cour Poulsen L, et al. Genetics and epigenetics in obesity. Metabolism. 2019;92:37–50.
   PubMed Web of Science ®Google Scholar
• Yengo L, Sidorenko J, Kemper KE, et al. Meta-analysis of genome-wide association studies for height and body mass index in approximately 700,000 individuals of European ancestry. Hum Mol Genet. 2018;27:3641–3649.
   PubMed Web of Science ®Google Scholar
• Ramos-Molina B, Martin MG, Lindberg I. PCSK1 variants and human obesity. Prog Mol Biol Transl Sci. 2016;140:47–74.
   PubMed Web of Science ®Google Scholar
• Ramachandrappa S, Raimondo A, Cali AM, et al. Rare variants in single-minded 1 (SIM1) are associated with severe obesity. J Clin Invest. 2013;123(7):3042–3050.
   PubMed Web of Science ®Google Scholar
• Rui L. SH2B1 regulation of energy balance, body weight, and glucose metabolism. World J Diabetes. 2014;5(4):511–526.
   PubMedGoogle Scholar
• Yeo GS, Connie Hung CC, Rochford J, et al. A de novo mutation affecting human TrkB associated with severe obesity and developmental delay. Nat Neurosci. 2004;7(11):1187–1189.
   PubMed Web of Science ®Google Scholar
• Zhang H, Ozbay F, Lappalainen J, et al. Brain derived neurotrophic factor (BDNF) gene variants and Alzheimer’s disease, affective disorders, posttraumatic stress disorder, schizophrenia, and substance dependence. Am J Med Genet B Neuropsychiatr Genet. 2006;141B(4):387–393.
   PubMed Web of Science ®Google Scholar
• Margolis SS, Sell GL, Zbinden MA, et al. Angelman Syndrome. Neurotherapeutics. 2015;12(3):641–650.
   PubMed Web of Science ®Google Scholar
• Raspa M, Bailey DB, Bishop E, et al. Obesity, food selectivity, and physical activity in individuals with fragile X syndrome. Am J Intellect Dev Disabil. 2010;115(6):482–495.
   PubMedGoogle Scholar
• Blacque OE, Leroux MR. Bardet-Biedl syndrome: an emerging pathomechanism of intracellular transport. Cell Mol Life Sci. 2006;63(18):2145–2161.
   PubMed Web of Science ®Google Scholar
• Marshall JD, Maffei P, Collin GB, et al. Alström syndrome: genetics and clinical overview. Curr Genomics. 2011;12(3):225–235.
   PubMed Web of Science ®Google Scholar
• Turner G, Lower KM, White SM, Delatycki M, et al. The clinical picture of the Börjeson-Forssman-Lehmann syndrome in males and heterozygous females with PHF6 mutations. Clin Genet. 2004;65(3):226–232.
   PubMed Web of Science ®Google Scholar
• Wilson M, Mulley J, Gedeon A, et al. New X-linked syndrome of mental retardation, gynecomastia, and obesity is linked to DXS255. Am J Med Genet A. 1991;40(4):406–413.
   Web of Science ®Google Scholar
• Rodrigues JM, Fernandes HD, Caruthers C, et al. Cohen syndrome: review of the literature. Cureus. 2018;10(9):e3330.
   PubMedGoogle Scholar
• Boscherini B, Coen G, Bianchini G, et al. Albright’s hereditary osteodystrophy. Acta Paediatr Scand. 1980;69(3):305–309.
   PubMed Web of Science ®Google Scholar
• Wilson LC, Hall CM. Albright’s hereditary osteodystrophy and pseudohypoparathyroidism. Semin Musculoskelet Radiol. 2002 Dec;6(4):273–283.
   PubMedGoogle Scholar
• Khan SF, Damerell V, Omar R, et al. The roles and regulation of TBX3 in development and disease. Gene. 2020;726:144223.
   PubMed Web of Science ®Google Scholar
• Tenorio J, Arias P, Martínez-Glez V, et al. Simpson-golabi-behmel syndrome types I and II. Orphanet J Rare Dis. 2014;9:138.
   PubMed Web of Science ®Google Scholar
• Funcke JB, von Schnurbein J, Lennerz B, et al. Monogenic forms of childhood obesity due to mutations in the leptin gene. Mol Cell Pediatr. 2014;1(1):3.
   PubMedGoogle Scholar
• Nunziata A, Borck G, Funcke JB, et al. Estimated prevalence of potentially damaging variants in the leptin gene. Mol Cell Pediatr. 2017;4(1):10.
   PubMedGoogle Scholar
• Yeo GSH, Chao DHM, Siegert AM, et al. The melanocortin pathway and energy homeostasis: from discovery to obesity therapy. Mol Metab. 2021;48:101206.
   PubMed Web of Science ®Google Scholar
• Martinelli CE, Keogh JM, Greenfield JR, et al. Obesity due to melanocortin 4 receptor (MC4R) deficiency is associated with increased linear growth and final height, fasting hyperinsulinemia, and incompletely suppressed growth hormone secretion. J Clin Endocrinol Metab. 2011;96(1):E181–8.
   PubMed Web of Science ®Google Scholar
• Angulo MA, Butler MG, Cataletto ME. Prader-Willi syndrome: a review of clinical, genetic, and endocrine findings. J Endocrinol Invest. 2015;38(12):1249–1263.
   PubMed Web of Science ®Google Scholar
• Mahmoud AM. An overview of epigenetics in obesity: the role of lifestyle and therapeutic interventions. Int J Mol Sci. 2022;23(3):1341.
   PubMed Web of Science ®Google Scholar
• Klemp I, Hoffmann A, Müller L, et al. DNA methylation patterns reflect individual lifestyle independent of obesity. Clin Transl Med. 2022;12:e851.
   PubMed Web of Science ®Google Scholar
• Rendell M, Ross DA, Drew HM, et al. Endogenous insulin secretion measured by c-peptide in maturity onset diabetes controllable by diet alone. Arch Int Med. 1981;141:1617–1622.
   PubMedGoogle Scholar
• Rendell M. C-peptide levels as a criterion in treatment of maturity onset diabetes. J Clin Endo Metab. 1983;57:1198–1206.
   PubMed Web of Science ®Google Scholar
• Rendell M. Editorial: dietary treatment of diabetes mellitus. N Engl J Med. 2000;342:1440–1441.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Aggressive weight reduction treatment in the management of type 2 diabetes. Diabetes Metab. 1998;24:116–123.
   PubMed Web of Science ®Google Scholar
• Kusminski CM, Bickel PE, Scherer PE. Targeting adipose tissue in the treatment of obesity-associated diabetes. Nat Rev Drug Discov. 2016;15:639–660.
   PubMed Web of Science ®Google Scholar
• Malin SK, Kashyap SR. Type 2 diabetes treatment in the patient with obesity. Endocrinol Metab Clin North Am. 2016;45:553–564.
   PubMed Web of Science ®Google Scholar
• Klein S, Sheard NF, Pi-Sunyer X, et al. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies. A statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Am J Clin Nutr. 2004;80:257–263.
   PubMed Web of Science ®Google Scholar
• Lindström J, Louheranta A, Mannelin M, et al. For the Finnish diabetes prevention study group. The Finnish Diabetes Prevention Study (DPS). Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care. 2003;26:3230–3236.
   PubMed Web of Science ®Google Scholar
• Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.
   PubMed Web of Science ®Google Scholar
• Lean MEJ, Leslie WS, Barnes AC, et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diab Endocrinol. 2019;7:344–355.
   PubMed Web of Science ®Google Scholar
• Martin CB, Herrick KA, Sarafrazi N, et al. Attempts to lose weight among adults in the United States, 2013–2016. NCHS Data Brief. 2018;313:1–8.
   Google Scholar
• Atallah R, Filion KB, Wakil SM, et al. Long-term effects of 4 popular diets on weight loss and cardiovascular risk factors. Circulation Cardiovasc Qual Outcomes. 2014;7:815–827.
   PubMed Web of Science ®Google Scholar
• Gardner CD, Trepanowski JF, Del Gobbo LC, et al. Effect of low-fat vs low-carbohydrate diet on 12-month weight loss in overweight adults and the association with genotype pattern or insulin secretion: the DIETFITS randomized clinical trial. JAMA. 2018;319:667–679.
   PubMed Web of Science ®Google Scholar
• Brouns F. Overweight and diabetes prevention: is a low-carbohydrate-high-fat diet recommendable? Eur J Nutr. 2018;57:1301–1312.
   PubMed Web of Science ®Google Scholar
• Kraschnewski JL, Boan J, Esposito J, et al. Long-term weight loss maintenance in the United States. Int J Obes. 2010;34:1644–1654.
   PubMed Web of Science ®Google Scholar
• Anderson JW, Konz EC, Frederich RC, et al. Long-term weight-loss maintenance: a meta-analysis of US studies. Am J Clin Nutr. 2001;74:579–584.
   PubMed Web of Science ®Google Scholar
• Look AHEAD Research Group, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. New Engl J Med. 2013;369:145–154.
   PubMed Web of Science ®Google Scholar
• Cătoi AF, Pârvu A, Mureşan A, et al. Metabolic mechanisms in obesity and type 2 diabetes: insights from bariatric/metabolic surgery. Obes Facts. 2015;8:350–363.
   PubMed Web of Science ®Google Scholar
• Arterburn DE, Courcoulas AP. Bariatric surgery for obesity and metabolic conditions in adults. BMJ. 2014;349:g3961.
   PubMedGoogle Scholar
• Courcoulas AP, Yanovski SZ, Bonds D, et al. Long-term outcomes of bariatric surgery: a National Institutes of Health symposium. JAMA Surg. 2014;149:1323–1329.
   PubMed Web of Science ®Google Scholar
• Ammori BJ, Skarulis MC, Soran H, et al. Medical and surgical management of obesity and diabetes: what’s new? Diabet Med. 2020;37:203–210.
   PubMed Web of Science ®Google Scholar
• Benaiges D, Más-Lorenzo A, Goday A, et al. Laparoscopic sleeve gastrectomy: more than a restrictive bariatric surgery procedure? World J Gastroenterol. 2015;21:11804–11814.
   PubMed Web of Science ®Google Scholar
• Salminen P, Helmiö M, Ovaska J, et al. Effect of laparoscopic sleeve gastrectomy vs laparoscopic Roux-en-Y gastric bypass on weight loss at 5 years among patients with morbid obesity: the SLEEVEPASS Randomized Clinical Trial. JAMA. 2018;319:241–254.
   PubMed Web of Science ®Google Scholar
• Colquitt JL, Pickett K, Loveman E, et al. Surgery for weight loss in adults. Cochrane Database Syst Rev. 2014;8:CD003641.
   PubMed Web of Science ®Google Scholar
• Topart P, Becouarn G, Ritz P. Weight loss is more sustained after biliopancreatic diversion with duodenal switch than Roux-en-Y gastric bypass in superobese patients. Surg Obes Relat Dis. 2013;9(4):526–530.
   PubMed Web of Science ®Google Scholar
• Prachand VN, Davee RT, Alverdy JC. Duodenal switch provides superior weight loss in the super-obese (BMI > or =50 kg/m2) compared with gastric bypass. Ann Surg. 2006;244(4):611–619.
   PubMed Web of Science ®Google Scholar
• Courcoulas AP, Belle SH, Neiberg RH, et al. Three-year outcomes of bariatric surgery vs lifestyle intervention for type 2 diabetes mellitus treatment: a randomized clinical trial. JAMA Surg. 2015;150(10):931–940.
   PubMed Web of Science ®Google Scholar
• Ienca R, Al Jarallah M, Caballero A, et al. The procedureless elipse gastric balloon program: multicenter experience in 1770 consecutive patients. Obes Surg. 2020;30(9):3354–3362.
   PubMed Web of Science ®Google Scholar
• Maciejewski ML, Arterburn DE, Van Scoyoc L, et al., Bariatric surgery and long-term durability of weight loss. JAMA Surg. 2016;151(11): 1046–1055.
   PubMed Web of Science ®Google Scholar
• Arterburn D, Wellman R, Emiliano A, et al; for the PCORnet bariatric study collaborative. Comparative effectiveness and safety of bariatric procedures for weight loss: a pcornet cohort study. Ann Intern Med. 2018;169(11):741–750.
   PubMed Web of Science ®Google Scholar
• Peterli R, Steinert RE, Woelnerhanssen B, et al. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. Obes Surg. 2012;22(5):740–748.
   PubMed Web of Science ®Google Scholar
• Cornejo-Pareja I, Clemente-Postigo M, Tinahones FJ. Metabolic and endocrine consequences of bariatric surgery. Front Endocrinol (Lausanne). 2019;10:626.
   PubMed Web of Science ®Google Scholar
• Steinert RE, Feinle-Bisset C, Asarian L, et al. Ghrelin, CCK, GLP-1, and PYY(3-36): secretory controls and physiological roles in eating and glycemia in health, obesity, and after RYGB. Physiol Rev. 2017;97(1):411–463.
   PubMed Web of Science ®Google Scholar
• Jones B, Sands C, Alexiadou K, et al. The metabolomic effects of tripeptide gut hormone infusion compared to Roux-en-Y gastric bypass and caloric restriction. J Clin Endocrinol Metab. 2022;107(2):e767–e782.
   PubMed Web of Science ®Google Scholar
• Steven S, Carey PE, Small PK, Steven S, Carey PE, Small PK, et al. Reversal of type 2 diabetes after bariatric surgery is determined by the degree of achieved weight loss in both short- and long-duration diabetes. Diabet Med. 2015;32(1):47–53.
   PubMed Web of Science ®Google Scholar
• McGlone ER, Carey I, Veličković V, et al. Bariatric surgery for patients with type 2 diabetes mellitus requiring insulin: clinical outcome and cost-effectiveness analyses. PLoS Med. 2020;17(12):e1003228.
   PubMed Web of Science ®Google Scholar
• Longitudinal Assessment of Bariatric Surgery (LABS) Consortium. Peri-operative safety in the longitudinal assessment of bariatric surgery. N Engl J Med. 2009;361(5):445–454.
   PubMed Web of Science ®Google Scholar
• Arterburn DE, Telem DA, Kushner RF, et al. Benefits and risks of bariatric surgery in adults: a review. JAMA. 2020;324(9):879–887.
   PubMed Web of Science ®Google Scholar
• Li RA, Liu L, Arterburn D, et al. Five-year longitudinal cohort study of reinterventions after sleeve gastrectomy and Roux-en-Y Gastric Bypass. Ann Surg. 2021;273(4):758–765.
   PubMed Web of Science ®Google Scholar
• Peterli R, Wölnerhanssen BK, Peters T, et al. Effect of laparoscopic sleeve gastrectomy vs laparoscopic Roux-en-Y gastric bypass on weight loss in patients with morbid obesity: the SM-BOSS randomized clinical trial. JAMA. 2018;319(3):255–265.
   PubMed Web of Science ®Google Scholar
• Stein J, Stier C, Raab H, et al. Review article: the nutritional and pharmacological consequences of obesity surgery. Aliment Pharmacol Ther. 2014;40(6):582–609.
   PubMed Web of Science ®Google Scholar
• Lupoli R, Lembo E, Saldalamacchia G, et al. Bariatric surgery and long-term nutritional issues. World J Diabetes. 2017;8(11):464–474.
   PubMed Web of Science ®Google Scholar
• Bal BS, Finelli FC, Shope TR, et al. Nutritional deficiencies after bariatric surgery. Nat Rev Endocrinol. 2012;8(9):544–556.
   PubMed Web of Science ®Google Scholar
• Nakamura KM, Haglind EG, Clowes JA, et al. Fracture risk following bariatric surgery: a population-based study. Osteoporos Int. 2014;25(1):151–158.
   PubMed Web of Science ®Google Scholar
• Faintuch J, Matsuda M, Cruz ME, et al. Severe protein-calorie malnutrition after bariatric procedures. Obes Surg. 2004;14(2):175–181.
   PubMed Web of Science ®Google Scholar
• Sjöström CD, Lissner L, Wedel H, et al. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res. 1999;7(5):477–484.
   PubMedGoogle Scholar
• Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357(8):741–752.
   PubMed Web of Science ®Google Scholar
• Aminian A, Wilson R, Al-Kurd A, et al. Association of bariatric surgery with cancer risk and mortality in adults with obesity. JAMA. 2022 June;327(24):2423–2433.
   PubMed Web of Science ®Google Scholar
• Wiggins T, Guidozzi N, Welbourn R, et al., Association of bariatric surgery with all-cause mortality and incidence of obesity-related disease at a population level: a systematic review and meta-analysis. PLoS Med. 2020;17(7): e1003206.
   PubMed Web of Science ®Google Scholar
• Syn NL, Cummings DE, Wang LZ, et al. Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174,772 participants. Lancet. 2021;397(10287):1830–1841.
   PubMed Web of Science ®Google Scholar
• Yerevanian A, Soukas AA. Metformin: mechanisms in human obesity and weight loss. Curr Obes Rep. 2019;8(2):156–164.
   PubMed Web of Science ®Google Scholar
• Chiasson JL, Josse RG, Gomis R, et al; STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359(9323):2072–2077.
   PubMed Web of Science ®Google Scholar
• Munro JF, MacCuish AC, Wilson EM, et al. Comparison of continuous and intermittent anorectic therapy in obesity. Br Med J. 1968;1(5588):352–354.
   PubMed Web of Science ®Google Scholar
• Moldovan CP, Weldon AJ, Daher NS, et al. Effects of a meal replacement system alone or in combination with phentermine on weight loss and food cravings. Obesity (Silver Spring). 2016;24(11):2344–2350.
   PubMed Web of Science ®Google Scholar
• Lewis KH, Fischer H, Ard J, et al., Safety and effectiveness of longer-term phentermine use: clinical outcomes from an electronic health record cohort. Obesity (Silver Spring). 2019;27(4): 591–602.
   PubMed Web of Science ®Google Scholar
• Li Z, Hong K, Yip I, et al. Body weight loss with phentermine alone versus phentermine and fenfluramine with very-low-calorie diet in an outpatient obesity management program: a retrospective study. Curr Ther Res Clin Exp. 2003;64(7):447–460.
   PubMed Web of Science ®Google Scholar
• Kancherla MK, Salti HI, Mulderink TA, et al. Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine. Am J Cardiol. 1999;84(11):1335–1338.
   PubMed Web of Science ®Google Scholar
• Araújo JR, Martel F. Sibutramine effects on central mechanisms regulating energy homeostasis. Curr Neuropharmacol. 2012;10(1):49–52.
   PubMed Web of Science ®Google Scholar
• Li MF, Cheung BM. Rise and fall of anti-obesity drugs. World J Diabetes. 2011;2(2):19–23.
   PubMedGoogle Scholar
• Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012;20(2):330–342.
   PubMed Web of Science ®Google Scholar
• Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011;19(1):110–120.
   PubMed Web of Science ®Google Scholar
• de Andrade Mesquita L, Fagundes Piccoli G, Richter da Natividade G, et al. Is lorcaserin really associated with increased risk of cancer? A systematic review and meta-analysis. Obes Rev. 2021;22(3):e13170.
   PubMed Web of Science ®Google Scholar
• Wabitsch M, Fehnel S, Mallya UG, et al. Understanding the patient experience of hunger and improved quality of life with setmelanotide treatment in POMC and LEPR Deficiencies. Adv Ther. 2022;39(4):1772–1783.
   PubMed Web of Science ®Google Scholar
• Ryan DH. Next generation antiobesity medications: setmelanotide, semaglutide, tirzepatide and bimagrumab: what do they mean for clinical practice? J Obes Metab Syndr. 2021 Sep 30;30(3):196–208.
   PubMed Web of Science ®Google Scholar
• Farr OM, Gavrieli A, Mantzoros CS. Leptin applications in 2015: what have we learned about leptin and obesity? Curr Opin Endocrinol Diabetes Obes. 2015;22(5):353–359.
   PubMedGoogle Scholar
• Ravussin E, Smith SR, Mitchell JA, et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring). 2009;17(9):1736–1743.
   PubMed Web of Science ®Google Scholar
• Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155–161.
   PubMed Web of Science ®Google Scholar
• Greenway FL, Aronne LJ, Raben A, et al. A randomized, double-blind, placebo-controlled study of Gelesis100: a novel nonsystemic oral hydrogel for weight loss. Obesity (Silver Spring). 2019 Feb;27(2):205–216.
   PubMed Web of Science ®Google Scholar
• Brown E, Heerspink HJL, Cuthbertson DJ, et al., SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet. 2021;398(10296): 262–276.
   PubMed Web of Science ®Google Scholar
• Arnott C, Li Q, Kang A, et al. Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. J Am Heart Assoc. 2020;9(3):e014908.
   PubMed Web of Science ®Google Scholar
• Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7(11):845–854.
   PubMed Web of Science ®Google Scholar
• Pereira MJ, Eriksson JW. Emerging role of SGLT-2 inhibitors for the treatment of obesity. Drugs. 2019;79(3):219–230.
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Iqbal N, Joen C, et al. Dapagliflozin monotherapy in drug-naive patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes Obes Metab. 2012;14(10):951–959.
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Ramos SJ, Salsali A, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33(10):2217–2224.
   PubMed Web of Science ®Google Scholar
• Ferrannini G, Hach T, Crowe S, et al. Energy balance after sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38(9):1730–1735.
   PubMed Web of Science ®Google Scholar
• Hall KD, Sacks G, Chandramohan D, et al., Quantification of the effect of energy imbalance on body weight. Lancet. 2011;378(9793): 826–837.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Quast DR, Wefers J, et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021;46:101102.
   PubMed Web of Science ®Google Scholar
• Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776–785.
   PubMed Web of Science ®Google Scholar
• Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015;314(7):687–699.
   PubMed Web of Science ®Google Scholar
• Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond). 2012;36(6):843–854.
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer X, Astrup A, Fujioka K, et al., A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1): 11–22.
   PubMed Web of Science ®Google Scholar
• Lean M, Carraro R, Finer N, et al. Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. Int J Obes. 2014;38(5):689–697.
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Buse JB, Taylor K, et al. DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372(9645):1240–1250.
   PubMed Web of Science ®Google Scholar
• Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne). 2019;10:155. DOI:10.3389/fendo.2019.00155.
   PubMed Web of Science ®Google Scholar
• Ahrén B, Atkin SL, Charpentier G, et al. Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. Diabetes Obes Metab. 2018;20(9):2210–2219.
   PubMed Web of Science ®Google Scholar
• O’Neil PM, Birkenfeld AL, McGowan B, et al., Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018;392(10148): 637–649.
   PubMed Web of Science ®Google Scholar
• Garvey WT, Batterham R, Bhatta M, et al. Two-year effect of semaglutide 2.4 mg vs placebo in adults with overweight or obesity (STEP 5). Presented at the 39th Annual Meeting of The Obesity Society (TOS) held at ObesityWeek®, Silver Spring, Maryland. November 1–5, 2021
   Google Scholar
• Andersen A, Knop FK, Vilsbøll T. A pharmacological and clinical overview of oral semaglutide for the treatment of type 2 diabetes. Drugs. 2021;81(9):1003–1030.
   PubMed Web of Science ®Google Scholar
• Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3(3):153–165.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Verdari I, Deacon CF, et al. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia. 2011;54(1):10–18.
   PubMed Web of Science ®Google Scholar
• Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Investig. 2014;124(10):4473–4488.
   PubMed Web of Science ®Google Scholar
• Kanoski SE, Hayes MR, Skibicka KP. GLP-1 and weight loss: unraveling the diverse neural circuitry. Am J Physiol Regul Integr Comp Physiol. 2016;310(10):R885–R895.
   PubMed Web of Science ®Google Scholar
• Dupre J. Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans. Regul Pept. 2005;128(2):149–157.
   PubMedGoogle Scholar
• Samms RJ, Coghlan MP, Sloop KW. How may GIP enhance the therapeutic efficacy of GLP-1? Trends Endocrinol Metab. 2020;31:410–421.
   PubMed Web of Science ®Google Scholar
• Yuliantie E, Darbalaei S, Dai A, et al. Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors. Biochem Pharmacol. 2020;177:114001.
   PubMed Web of Science ®Google Scholar
• Frias JP, Nauck MA, Van J, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018;392:2180–2193.
   PubMed Web of Science ®Google Scholar
• Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385:503–515.
   PubMed Web of Science ®Google Scholar
• Jastreboff AM, Aronne LJ, Ahmad NN. SURMOUNT-1 Investigators Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022 Jun;387:205–216.
   PubMed Web of Science ®Google Scholar
• Habegger KM, Heppner KM, Geary N, et al. The metabolic actions of glucagon revisited. Nat Rev Endocrinol. 2010;6(12):689–697.
   PubMed Web of Science ®Google Scholar
• Sanchez-Garrido MA, Brandt SJ, Clemmensen C, et al. GLP-1/glucagon receptor co-agonism for treatment of obesity. Diabetologia. 2017;60(10):1851–1861.
   PubMed Web of Science ®Google Scholar
• Salem V, Izzi-Engbeaya C, Coello C, et al. Glucagon increases energy expenditure independently of brown adipose tissue activation in humans. Diabetes Obes Metab. 2016;18:72–81.
   PubMed Web of Science ®Google Scholar
• Matthias H, Tschöp MH, Brian Finan B, Christoffer Clemmensen C, et al. Unimolecular polypharmacy for treatment of diabetes and obesity. Cell Metab. 2016;24:51–62.
   PubMed Web of Science ®Google Scholar
• Knerr PJ, Mowery SA, Douros JD, et al. Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice. Mol Metab. 2022;63:101533.
   PubMed Web of Science ®Google Scholar
• Tillner J, Posch MG, Wagner F, et al. A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: results of randomized, placebo-controlled first-in-human and first-in-patient trials. Diabetes Obes Metab. 2019;21(1):120–128.
   PubMed Web of Science ®Google Scholar
• Visentin R, Schiavon M, Göbel B, et al. Man. Dual glucagon-like peptide-1 receptor/glucagon receptor agonist SAR425899 improves beta-cell function in type 2 diabetes. Diabetes Obes Metab. 2020;22:640–647.
   PubMed Web of Science ®Google Scholar
• Baggio LL, Drucker DJ. Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease. Mol Metab. 2021;46:101090.
   PubMed Web of Science ®Google Scholar
• Li L, Shen JJ, Bournat JC, et al. Activin signaling: effects on body composition and mitochondrial energy metabolism. Endocrinology. 2009;150(8):3521–3529.
   PubMed Web of Science ®Google Scholar
• Heymsfield SB, Coleman LA, Miller R, et al. Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial. JAMA Network Open. 2021;4(1):e2033457.
   PubMed Web of Science ®Google Scholar
• Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism. 2019;92:6–10.
   PubMed Web of Science ®Google Scholar
• Swinburn B, Ley S, Carmichael H, et al. Body size and composition in Polynesians. Int J Obes. 1999;23:1178–1183.
   PubMed Web of Science ®Google Scholar
• Kaholokula JK, Townsend CK, Ige A, et al. Sociodemographic, behavioral, and biological variables related to weight loss in native Hawaiians and other Pacific Islanders. Obesity (Silver Spring). 2013;21:E196–203.
   PubMed Web of Science ®Google Scholar
• Price RA, Charles MA, Pettitt DJ, et al. Obesity in Pima Indians: large increases among post-World War II birth cohorts. Am J Phys Anthropol. 1993;92:473–479.
   PubMed Web of Science ®Google Scholar
• Jih J, Mukherjea A, Vittinghoff E, et al. Using appropriate body mass index cut points for overweight and obesity among Asian Americans. Prev Med. 2014;65:1–6.
   PubMed Web of Science ®Google Scholar
• Nathan DM. DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014;37:9–16.
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589.
   PubMed Web of Science ®Google Scholar
• Rendell M. Pharmacotherapeutic options for prediabetes. Expert Opin Pharmacother. 2021;22:45–54.
   PubMed Web of Science ®Google Scholar
• Kilov D, Kilov G. Philosophical determinants of obesity as a disease. Obes Rev. 2018;19:41–48.
   PubMed Web of Science ®Google Scholar
• Chalklin CG, Ryan Harper EG, Beamish AJ. Metabolic and bariatric surgery in adolescents. Curr Obes Rep. 2021;10:61–69.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
   PubMed Web of Science ®Google Scholar
• Mahaffey KW, Neal B, Perkovic V, et al; CANVAS program collaborative group. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin cardiovascular assessment study). Circulation. 2018;137:323–334.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347–357.
   PubMed Web of Science ®Google Scholar
• Petrie MC, Verma S, Docherty KF, et al. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without. JAMA. 2020;323:1353–1368.
   PubMed Web of Science ®Google Scholar
• Lytvyn Y, Bjornstad P, Udell JA, et al. Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Circulation. 2017;136:1643–1658.
   PubMed Web of Science ®Google Scholar
• Cardoso R, Graffunder FP, Ternes CMP, et al. SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: a systematic review and meta-analysis. EClinicalMedicine. 2021;36:100933.
   PubMedGoogle Scholar
• Pedersen TR. The success story of LDL cholesterol lowering. Circ Res. 2016 Feb 19; 118(4):721–731.
   PubMed Web of Science ®Google Scholar